SCHEMBL28894342

SCHEMBL28894342

O=C(O)c1ccc(/C=C\CBr)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 6/20 0.46
PKM P14618 1/20 0.38
LIG1 P18858 1/20 0.38
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
RARB P10826 2/20 0.35
RARG P13631 2/20 0.35
RXRA P19793 2/20 0.35
RXRB P28702 2/20 0.35
RXRG P48443 2/20 0.35
RARA P10276 1/20 0.35
GSK3B P49841 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
HPGD P15428 1/20 0.33
HPGDS O60760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057270 1.00 DAO (0.46) DAOPKMLIG1KMT2AMEN1
SCHEMBL17475242 1.00 DAO (0.46) DAOPKMLIG1KMT2AMEN1
SCHEMBL16088586 0.83 NPSR1 (0.45) PKMKMT2AMEN1POLBRAB9A
SCHEMBL16401728 0.83 NPSR1 (0.45) PKMKMT2AMEN1POLBRAB9A
SCHEMBL15550265 0.83 NPSR1 (0.45) PKMKMT2AMEN1POLBRAB9A
SCHEMBL22380001 0.82 DAO (0.52) DAOPKMLIG1KMT2AMEN1
SCHEMBL10023944 0.76 DAO (0.50) DAOPKMLIG1KMT2AMEN1
SCHEMBL8435188 0.73 ALOX5 (0.48) DAOKMT2AMEN1POLBRAB9A
SCHEMBL8435184 0.73 ALOX5 (0.48) DAOKMT2AMEN1POLBRAB9A
SCHEMBL8437696 0.73 ALOX5 (0.48) DAOKMT2AMEN1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107802623-B Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders 开曼化学股份有限公司 2020-10-30 CN disclosed
CN-106748951-B Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions 开曼化学股份有限公司 2020-07-24 CN disclosed